Should I buy or sell 2seventy bio stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last year. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TSVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TSVT, but not buy additional shares or sell existing shares. View TSVT analyst ratings or view top-rated stocks .

What is 2seventy bio's stock price target for 2024?

7 analysts have issued 12 month price objectives for 2seventy bio's shares. Their TSVT share price targets range from $4.00 to $26.00. On average, they anticipate the company's share price to reach $11.17 in the next year. This suggests a possible upside of 475.6% from the stock's current price. View analysts price targets for TSVT or view top-rated stocks among Wall Street analysts .

How have TSVT shares performed in 2023?

2seventy bio's stock was trading at $9.37 at the beginning of the year. Since then, TSVT stock has decreased by 79.3% and is now trading at $1.94. View the best growth stocks for 2023 here .

When is 2seventy bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our TSVT earnings forecast .

What ETFs hold 2seventy bio's stock?

ETFs with the largest weight of 2seventy bio (NASDAQ:TSVT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) , Horizon Kinetics Medical ETF (MEDX) , Goldman Sachs Future Health Care Equity ETF (GDOC) . Global X Genomics & Biotechnology ETF (GNOM) ,

Who are 2seventy bio's major shareholders?

2seventy bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Kynam Capital Management LP (11.80%), Newtyn Management LLC (6.10%), Wellington Management Group LLP (5.91%), CHI Advisors LLC (1.99%), Jacobs Levy Equity Management Inc. (1.54%) and Charles Schwab Investment Management Inc. (1.08%). Insiders that own company stock include Kynam Capital Management, Lp, Nick Leschly , Nicola Heffron , Philip D Gregory and William D Baird III . View institutional ownership trends .

How do I buy shares of 2seventy bio?

Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

2seventy bio Stock Price, News & Analysis (NASDAQ:TSVT)

$1.94

+0.11 (+6.01%)

(As of 12/1/2023 08:55 PM ET)

Compare

Today's Range: $1.68
▼
$1.95
50-Day Range: $1.57
▼
$4.49
52-Week Range: $1.54
▼
$16.17

Volume: 775,200 shs
Average Volume: 1.17 million shs
Market Capitalization: $98.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.17

2seventy bio MarketRank™ Stock Analysis

Analyst Rating: Hold
2.14 Rating Score
Upside/Downside: 475.6% Upside
$11.17 Price Target
Short Interest: Bearish
26.17% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.96
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.99) to ($1.65) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

369th out of 957 stocks

Pharmaceutical Preparations Industry

158th out of 436 stocks

4.1

Analyst's Opinion

Consensus Rating
2seventy bio has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.17, 2seventy bio has a forecasted upside of 475.6% from its current price of $1.94.
Amount of Analyst Coverage
2seventy bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
26.17% of the float of 2seventy bio has been sold short.
Short Interest Ratio / Days to Cover
2seventy bio has a short interest ratio ("days to cover") of 6.6.
Change versus previous month
Short interest in 2seventy bio has recently increased by 8.84%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
2seventy bio does not currently pay a dividend.
Dividend Growth
2seventy bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TSVT.

2.8

News and Social Media Coverage

News Sentiment
2seventy bio has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for 2seventy bio this week, compared to 2 articles on an average week.
Search Interest
8 people have searched for TSVT on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 2seventy bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.60% of the stock of 2seventy bio is held by insiders.
Percentage Held by Institutions
98.49% of the stock of 2seventy bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for 2seventy bio are expected to grow in the coming year, from ($3.99) to ($1.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of 2seventy bio is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 2seventy bio is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
2seventy bio has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About 2seventy bio Stock (NASDAQ:TSVT)

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and chimeric antigen receptor-T cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

TSVT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TSVT Stock News Headlines

November 30, 2023 | markets.businessinsider.com

Biotech Stocks Facing FDA Decision In December 2023

November 24, 2023 | americanbankingnews.com

Wedbush Research Analysts Raise Earnings Estimates for 2seventy bio, Inc. (NASDAQ:TSVT)

December 4, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 23, 2023 | markets.businessinsider.com

Hold Rating for 2seventy Bio Amid Regulatory Risks and Potential Upsides: An Analysis on KarMMa-3 Study Outcomes and Stock Performance

November 21, 2023 | msn.com

Wedbush Downgrades 2seventy bio (TSVT)

November 20, 2023 | msn.com

Bristol Myers Squibb slumps as FDA convenes advisory panel for drug application

November 20, 2023 | bizjournals.com

2seventy slides on latest roadblock for cancer drug

November 20, 2023 | reuters.com

US FDA delays decision on Bristol Myers-2seventy bio cancer therapy

December 4, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 17, 2023 | markets.businessinsider.com

Daina Graybosch Maintains ‘Hold’ Rating for 2seventy Bio Amid Revenue Decline and Market Challenges

November 14, 2023 | finance.yahoo.com

2seventy bio Inc (TSVT) Reports Q3 Financial Results Amid Competitive Market Dynamics

November 14, 2023 | benzinga.com

2seventy bio: Q3 Earnings Insights

November 13, 2023 | markets.businessinsider.com

2seventy bio earnings: here's what Wall Street expects

November 13, 2023 | benzinga.com

Preview: 2seventy bio's Earnings

November 10, 2023 | finance.yahoo.com

2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023

October 30, 2023 | msn.com

Leerink Partners Downgrades 2seventy bio (TSVT)

October 30, 2023 | finance.yahoo.com

2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?

October 13, 2023 | msn.com

Citigroup Initiates Coverage of 2seventy bio (TSVT) with Buy Recommendation

September 18, 2023 | bizjournals.com

2seventy bio reveals how many in Cambridge will be cut in mass layoff

September 14, 2023 | reuters.com

2seventy bio to lay off 40% of workforce

September 13, 2023 | msn.com

Goldman Sachs Downgrades 2seventy bio (TSVT)

September 13, 2023 | markets.businessinsider.com

2seventy Bio's Cost Cuts Prudent But Analyst Says It Induces Lower Confidence In Lead Product

September 13, 2023 | msn.com

Guggenheim Downgrades 2seventy bio (TSVT)

September 12, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for 2seventy bio

September 12, 2023 | reuters.com

2seventy bio CEO to step down, plans job cuts

September 12, 2023 | markets.businessinsider.com

2seventy Bio Announces Restructuring, To Reduce 176 Roles

September 12, 2023 | finance.yahoo.com

2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies

See More Headlines

Receive TSVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 12/03/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TSVT
CUSIP: N/A
CIK: 1860782
Web: www.2seventybio.com
Phone: 339-499-9300
Fax: N/A
Employees: 425
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.17
High Stock Price Target: $26.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +475.6%
Consensus Rating: Hold
Rating Score (0-4): 2.14
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.91)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-254,150,000.00
Net Margins: -126.06%
Pretax Margin: -126.06%
Return on Equity: -47.12%
Return on Assets: -23.78%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.08
Quick Ratio: 4.08

Sales & Book Value

Annual Sales: $91.50 million
Price / Sales: 1.07
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.05 per share
Price / Book: 0.32

Miscellaneous

Outstanding Shares: 50,630,000
Free Float: 49,309,000
Market Cap: $98.22 million
Optionable: Not Optionable
Beta: 1.14

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Nick Leschly (Age 50)
President, CEO & Director
Comp: $1.81M
Dr. Philip D. Gregory D. Phil. (Age 52)
DPHIL, Chief Scientific Officer
Comp: $1.01M
Mr. William D. Baird III (Age 51)
M.B.A., Principal Financial Officer, Principal Accounting Officer & Chief Operating Officer
Comp: $810.83k
Ms. Susan Abu-Absi Ph.D.
Chief Technology Officer
Ms. Teresa L. Jurgensen J.D.
Senior VP, General Counsel & Corporate Secretary
Ms. Kerri Jensen
Head of People & Culture
Ms. Jenn Snyder
Senior Vice President of Corporate Affairs
Dr. Steven Bernstein M.D.
Chief Medical Officer
Michael Certo
VP & Head of Genome Editing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TSVT Stock Analysis - Frequently Asked Questions

Should I buy or sell 2seventy bio stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last year. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TSVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TSVT, but not buy additional shares or sell existing shares.
View TSVT analyst ratings or view top-rated stocks.
What is 2seventy bio's stock price target for 2024?: 7 analysts have issued 12 month price objectives for 2seventy bio's shares. Their TSVT share price targets range from $4.00 to $26.00. On average, they anticipate the company's share price to reach $11.17 in the next year. This suggests a possible upside of 475.6% from the stock's current price.
View analysts price targets for TSVT or view top-rated stocks among Wall Street analysts.
How have TSVT shares performed in 2023?: 2seventy bio's stock was trading at $9.37 at the beginning of the year. Since then, TSVT stock has decreased by 79.3% and is now trading at $1.94.
View the best growth stocks for 2023 here.
When is 2seventy bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our TSVT earnings forecast.

What ETFs hold 2seventy bio's stock?: ETFs with the largest weight of 2seventy bio (NASDAQ:TSVT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Horizon Kinetics Medical ETF (MEDX), Goldman Sachs Future Health Care Equity ETF (GDOC).Global X Genomics & Biotechnology ETF (GNOM),
Who are 2seventy bio's major shareholders?: 2seventy bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Kynam Capital Management LP (11.80%), Newtyn Management LLC (6.10%), Wellington Management Group LLP (5.91%), CHI Advisors LLC (1.99%), Jacobs Levy Equity Management Inc. (1.54%) and Charles Schwab Investment Management Inc. (1.08%). Insiders that own company stock include Kynam Capital Management, Lp, Nick Leschly, Nicola Heffron, Philip D Gregory and William D Baird III.
View institutional ownership trends.
How do I buy shares of 2seventy bio?: Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TSVT) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial